Overview Infliximab for Treatment of Ipilimumab Colitis Status: Recruiting Trial end date: 2023-06-30 Target enrollment: Participant gender: Summary This research study is evaluating the effectiveness and safety of infliximab therapy compared with steroids in the treatment of ipilimumab-induced colitis in patients with III/IV melanoma. Phase: Phase 2 Details Lead Sponsor: Massachusetts General HospitalTreatments: InfliximabIpilimumabMethylprednisoloneMethylprednisolone AcetateMethylprednisolone HemisuccinatePrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphatePrednisone